Terapia Génica del Cáncer
TGC
Weizmann Institute of Science
Rejovot, IsraelPublikationen in Zusammenarbeit mit Forschern von Weizmann Institute of Science (2)
2022
-
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
Nature Cancer, Vol. 3, Núm. 11, pp. 1336-1350
-
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)
Nature Cancer